The safety and effectiveness of Ultomiris (ravulizumab-cwvz) as a maintenance therapy for children and adolescents with atypical hemolytic uremic syndrome (aHUS) remained unchanged even when the drug was administered at lower doses, not using the patient’s weight as a guide. That’s according to a new, small study that…